Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

Becton Dickinson and Co Profile



Ticker SymbolBDX

Company nameBecton Dickinson and Co

IPO dateOct 31, 2099

CEOPolen (Thomas E)

Number of employees72000

Security typeOrdinary Share

Fiscal year-endOct 31

AddressOne Becton Drive

CityFRANKLIN LAKES

Stock exchangeNASDAQ OMX NASDAQ Basic NYSE

CountryUnited States of America

Postal code07417-1880

Phone12018476800

Websitehttps://www.bd.com/

Ticker SymbolBDX

IPO dateOct 31, 2099

CEOPolen (Thomas E)

Company Executives of Becton Dickinson and Co



Name

Name/Position

Position

Shareholding

Change

Mr. Timothy M. (Tim) Ring

Independent Director

61.16K

+1.80%

Ms. Shana Carol Neal

Chief People Officer, Executive Vice President

53.67K

-2.14%

Mr. Bilal Muhsin

Executive Vice President, President - Connected Care Segment

34.16K

+36.32%

Ms. Catherine M. (Cathy) Burzik

Independent Director

14.92K

+0.78%

Mr. Roland Goette

Executive Vice President, President - EMEA

14.78K

-16.50%

Mr. Peter Menziuso

Executive Vice President, President - BD Interventional

14.26K

Mr. Robert Andrew (Andy) Eckert

Independent Director

10.38K

+10.57%

Mr. Gregory J. Hayes

Independent Director

7.15K

+15.35%

Mr. Vitor Roque

Chief Financial Officer, Executive Vice President

6.94K

-2.74%

Dr. Carrie L. Byington, M.D.

Independent Director

6.64K

+16.54%

Name

Name/Position

Position

Shareholding

Change

Mr. Timothy M. (Tim) Ring

Independent Director

61.16K

+1.80%

Ms. Shana Carol Neal

Chief People Officer, Executive Vice President

53.67K

-2.14%

Mr. Bilal Muhsin

Executive Vice President, President - Connected Care Segment

34.16K

+36.32%

Ms. Catherine M. (Cathy) Burzik

Independent Director

14.92K

+0.78%

Mr. Roland Goette

Executive Vice President, President - EMEA

14.78K

-16.50%

Mr. Peter Menziuso

Executive Vice President, President - BD Interventional

14.26K

FAQs

Who are the top five shareholders of Becton Dickinson and Co?



The top five shareholders of Becton Dickinson and Co are: Mr. Timothy M. (Tim) Ring

How many institutions hold shares of Becton Dickinson and Co (BDX)?



As of 2026Q1, 2890 institutions hold shares of Becton Dickinson and Co, with a combined market value of approximately 241.06M, accounting for 87.47% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -46775483.00.

What is the biggest source of revenue for Becton Dickinson and Co?



In 2026Q1, the Medication Delivery Solutions business generated the highest revenue for Becton Dickinson and Co, amounting to 1.16B and accounting for 23.36% of total revenue.